Illumina Inc. (ILMN-Q) Stock Predictions - Stockchase
WATCH LIST
2
Illumina Inc. (ILMN-Q)

ON STOCKCHASE SINCE Oct 2013

Gene sequencing products.

Consumer Products

Illumina Inc.

ILMN-Q

9 watching          
Join the Discussion

Illumina Inc. (ILMN-Q) SAVE Apr, 19, 2019, 9:14 am

319.03 0.34 (0.11%)

About Illumina Inc. (ILMN-Q)

Illumina, Inc. is an American company incorporated in April 1998 that develops, manufactures and markets integrated systems for the analysis of genetic variation and biological function. More at Wikipedia

What the experts are saying about ILMN-Q



  • All
  • Filtered
Signal Opinion Expert
TOP PICK
Illumina Inc.(ILMN-Q) 

July 18, 2018

He is a big believer in disrupter companies in growth sectors.  This is the only company in the world that can do high volume DNA sequencing.  They already have a million customers and another million order backlog.  There is no one else in this space.  They sell equipment and the supplies to operate the equipment.  Countries will have more DNA sequencing done to help new drug development.  Yield 0%. (Analysts’ price target is $286.06)

Consumer Products
0 0 0 0 0
0 comments

He is a big believer in disrupter companies in growth sectors.  This is the only company in the world that can do high volume DNA sequencing.  They already have a million customers and another million order backlog.  There is no one else in this space.  They sell equipment and the supplies to operate the equipment.  Countries will have more DNA sequencing done to help new drug development.  Yield 0%. (Analysts’ price target is $286.06)

Consumer Products
0 0 0 0 0
0 comments
David Burrows

President , Barometer Capital Ma...

Price Price
$307.280
Owned Owned
Yes

COMMENT
Illumina Inc.(ILMN-Q) 

October 28, 2013

Dominant player in gene sequencing business.  Becoming more commercially available to clinics instead of just research labs.  They are buying up some of their customers and going into competition with them.  He is nervous of the valuation.  It is at and beyond his expectations.

Consumer Products
0 0 0 0 0
0 comments

Dominant player in gene sequencing business.  Becoming more commercially available to clinics instead of just research labs.  They are buying up some of their customers and going into competition with them.  He is nervous of the valuation.  It is at and beyond his expectations.

Consumer Products
0 0 0 0 0
0 comments
Ian Ainsworth

Vice Presi, MacKenzie Financial ...

Price Price
$92.760
Owned Owned
Unknown

Showing 1 to 2 of 2 entries
Successfully Saved Company
Successfully Saved Company
4+
JOIN THE DISCUSSION
4 comments in the last 7 days